Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Evaluation of Dexmedetomidine for EBUS-TBNA
NCT01381627Phase 4Unknown
- Sponsor
- Hôpital Maisonneuve-Rosemont
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in lung cancer (2 arms), sponsored by Hôpital Maisonneuve-Rosemont. Primary endpoint: Major adverse events at 1 day. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT01381627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381627.